ArticleClinical ophthalmology (Auckland, N.Z.)2026
Outcomes of Therapeutic and Tectonic Penetrating Keratoplasty for Advanced Corneal Disease.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate graft survival, clinical outcomes, and prognostic factors after therapeutic and tectonic penetrating keratoplasty (PKP) in a tertiary eye care center in Saudi Arabia. Methods: This retrospective study analyzed the medical records of all patients who underwent therapeutic or tectonic PKP between June 2014 and December 2020 at King Khaled Eye Specialist Hospital in Riyadh, Saudi Arabia. Inclusion criteria required at least a two-year follow-up for clear grafts. Data collected included demographics, preoperative characteristics, surgical details, postoperative visual acuity, graft survival, and complications. Kaplan-Meier survival analysis was performed, and risk factors for graft failure were evaluated. Results: Ninety eyes from 90 patients met the inclusion criteria. The mean age was 52.0 ± 23.5 years, and 55.5% of patients were male. The mean follow-up was 3.8 ± 1.2 years (range 2.1-6.4 years). The most common indication was microbial keratitis (76.7%), followed by autoimmune disease (8.9%) and trauma (5.6%). The mean donor graft size was 8.91 ± 1.67 mm. Kaplan-Meier cumulative graft survival was 48.2% at 1 year, 27.8% at 2 years, and 24.4% at 3 and 4 years. Larger graft size was the only significant risk factor for graft failure (p < 0.001). The most common complications were glaucoma (46.6%), persistent epithelial defect (37.8%), and persistent infection (31.0%). Visual acuity improved in 10.0%, remained stable in 75.6%, and deteriorated in 14.4% of cases. Conclusion: Therapeutic and tectonic PKP preserved globe integrity in most eyes but were associated with poor graft survival, limited visual recovery, and frequent postoperative complications in this high-risk cohort. These findings are consistent with presentation at an advanced stage of disease in a tertiary referral setting, as reflected by large graft size and poor baseline visual acuity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.